C

Coherus BioSciences
D

CHRS

0.70610
USD
-0.02
(-3.06%)
مغلق
حجم التداول
109,534
الربح لكل سهم
0
العائد الربحي
0
P/E
-2
حجم السوق
81,348,780
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    C
    CHRA
    -0.42000
    (-9.84%)
    3.85000 USD
    C
    CRIS
    -0.60000
    (-11.05%)
    4.83000 USD
    H
    HSDT
    -0.02260
    (-3.16%)
    0.69340 USD
الأخبار
المقالات

العنوان: Coherus BioSciences

القطاع: Healthcare
الصناعة: Biotechnology
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.